trump glp 1 deal President Donald announced Thursday a with drugmakers Novo Nordisk and Eli Lilly to lower the cost of the GLP-1 weight-loss drugs Wegovy and Zepbound., The deal will expand access for those Trump's Innovative Drug Price Deals:

Description

Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver ...

This analytical review critically examines the evidence surrounding GLP-1 agonists efficacy, safety, and real-world implications for obesity treatment in individuals without diabetes

This companion panel helps you get a clearer wellness snapshot-so you're tracking more than weight alone, with practical lab insights you can adjust your diet, improve your fitness routine, or simply stay informed about your body, this test provides a convenient way to monitor changes over time Liver Function and Cholesterol Check-In: Includes liver function and cholesterol markers to support a smarter metabolism check-in during your program-especially helpful when your habits, dose, or weight trend is shifting Added Awareness for Potential Pancreatic Stress: Amylase and Lipase trends provide important early awareness of pancreatic strain, a key concern for many GLP-1 users Kidney Function Awareness for Hydration Shifts: Appetite changes and lower intake can impact hydration